NADRAVALEUCEL
UNII S2RRP2SH5H

Substance Identification & Data

This profile provides standardized clinical and technical data for Nadravaleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) S2RRP2SH5H.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

S2RRP2SH5H

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NADRAVALEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C187130

National Cancer Institute reference terminology for clinical and research data.

INN ID

12339

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-191

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nadravaleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NADRAVALEUCEL

Common Names & Synonyms

ALLOGENEIC NATURAL KILLER (NK) CELLS ISOLATED FROM PERIPHERAL BLOOD LEUKAPHERESIS OF INDIVIDUAL DONORS. THE CELLS ARE CO-CULTURED IN MEDIA CONTAINING INTERLEUKIN 15 (IL-15) AND NICOTINAMIDE (NAM, NIACINAMIDE) WITH EXPANSION ENHANCED BY THE PRESENCE OF FEEDER CELLS. THE FINAL CELL POPULATION CONSISTS OF 97-99% CD3-CD56+ NK CELLS, WITH >10% EXPRESSING CD16 (ALSO KNOWN AS FC.GAMMA.RIII) AND CD62L (ALSO KNOWN AS L-SELECTIN) AND WITH CAPACITY TO DEGRANULATE (SURFACE EXPRESSION OF CD107.ALPHA. (LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN 1); >10%), AND TO KILL TARGET CELLS (>10%) IN CO-CULTURE ASSAYS AGAINST HUMAN CANCER CELL LINES.

NADRAVALEUCEL [USAN]

Technical Codes

GDA-201

External Clinical & Regulatory Resources

Previous UNIIS2RK3N86CL

Next UNIIS2SFZ0Z4TW